Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms
Experimental Hematology · 2024
DOI: 10.1016/j.exphem.2024.104178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Hematology, 2024. Verfasst von Taylor B Collins und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Neoplasms, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
Myeloproliferative neoplasms (MPNs) are driven by hyperactivation of JAK-STAT signaling but can demonstrate skewed hematopoiesis upon acquisition of additional somatic mutations. Here, using primary MPN samples and engineered embryonic stem cells, we demonstrate that mutations in JAK2 induced a significant increase in erythroid colony formation, whereas mutations in additional sex combs-like 1 (ASXL1) led to an erythroid colony defect. RNA-sequencing revealed upregulation of protein arginine methyltransferase 6 (PRMT6) induced by mutant ASXL1. Furthermore, genetic perturbation of PRMT6 exacerbated the MPN disease burden, including leukemic engraftment and splenomegaly, in patient-derived xenograft models, highlighting a novel tumor-suppressive function of PRMT6. However, augmented erythroid potential and bone marrow human CD71+ cells following PRMT6 knockdown were reserved only for primary MPN samples harboring ASXL1 mutations. Last, treatment of CD34+ hematopoietic/stem progenitor cells with the PRMT6 inhibitor EPZ020411 induced expression of genes involved in heme metabolism, hemoglobin, and erythropoiesis. These findings highlight interactions between JAK2 and ASXL1 mutations and a unique erythroid regulatory network in the context of mutant ASXL1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY; Depart…
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Center for Genome Integrity, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; Immunomonitoring…
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- Foundation for Barnes-Jewish Hospital
- Siteman Cancer Center
Zitieren
APA
Collins, T. B., Laranjeira, A. B. A., Kong, T., Fulbright, M. C., Fisher, D. A. C., Sturgeon, C. M., Batista, L. F. Z., & Oh, S. T. (2024). Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms. Experimental Hematology. https://doi.org/10.1016/j.exphem.2024.104178
Vancouver
Collins TB, Laranjeira ABA, Kong T, Fulbright MC, Fisher DAC, Sturgeon CM, et al. Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms. Experimental Hematology. 2024. doi:10.1016/j.exphem.2024.104178
BibTeX
@article{Collins2024,
author = {Collins, Taylor B and Laranjeira, Angelo B A and Kong, Tim and Fulbright, Mary C and Fisher, Daniel A C and Sturgeon, Christopher M and Batista, Luis F Z and Oh, Stephen T},
title = {Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms},
journal = {Experimental Hematology},
year = {2024},
doi = {10.1016/j.exphem.2024.104178}
}
EUVIMED